Recent Updates
Recently added Catalysts

Pneumococcal Disease Prophylaxis: one US-listed biotech with a clinical-stage programme

Infectious Disease & VaccinesUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$9.1Buniverse median $1.20B
Allocated capital$4.6B$9.1B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank41/299crowding rank 104

Pneumococcal Disease Prophylaxis is uncontested. Vaxcyte (PCVX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with dose of PCV20 in phase 3.

There is no public comparable to price it against. PCVX spreads its $9.1B market cap across 2 indications, so $4.6B of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$4.6B of allocated capital sits in Pneumococcal Disease Prophylaxis, ranking it 41st of 299 indications by the money committed to it.

Companies developing drugs for Pneumococcal Disease Prophylaxis 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
PCVXVaxcytedose of PCV20Phase 311$9.1BNo2 31 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Pneumococcal Disease Prophylaxis counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Pneumococcal Disease Prophylaxis has one competitor and a median of $9.1B.

Infectious Disease & Vaccines

Infectious Disease & Vaccines holds $16.5B of the map's capital, 2.5% of the total, spread across 13 indications and 10 companies. 0 of those indications have more than one company competing.

See every Infectious Disease & Vaccines indication on the map

Related indications in Infectious Disease & Vaccines

Streptococcal Infections1 company · $4.6B · median $9.1BUncontestedLyme Disease1 company · $1.8B · median $3.7BUncontestedHepatitis1 company · $1.3B · median $2.5BUncontestedMycobacterium Abscessus Infection1 company · $771M · median $1.5BUncontestedIntra-Abdominal Infections1 company · $771M · median $1.5BUncontestedSepsis1 company · $723M · median $8.7BUncontestedChronic Hepatitis B1 company · $484M · median $1.9BUncontestedCompensated Chronic Hepatitis B1 company · $484M · median $1.9BUncontested

Pneumococcal Disease Prophylaxis pipeline questions

Which biotech companies are developing drugs for Pneumococcal Disease Prophylaxis?

Vaxcyte (PCVX, dose of PCV20, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Pneumococcal Disease Prophylaxis.

How advanced is the Pneumococcal Disease Prophylaxis pipeline?

Of the 1 clinical-stage programme in Pneumococcal Disease Prophylaxis, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Pneumococcal Disease Prophylaxis?

No. PCVX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Pneumococcal Disease Prophylaxis, which is why the indication is classified as uncontested.

When is the next Pneumococcal Disease Prophylaxis catalyst?

The next dated catalyst in Pneumococcal Disease Prophylaxis is PCVX on 31 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map